Open AccessEffects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials
Author(s) -
Ray Meng See,
Yao Neng Teo,
Yao Hao Teo,
Nicholas Syn,
Alicia Swee Yan Yip,
Shariel Leong,
Caitlin Fern Wee,
Alex Jia Yang Cheong,
ChiHang Lee,
Mark Y Chan,
Tiong Cheng Yeo,
Raymond Wong,
Peter Chang,
Choon Chiet Hong,
Ping Chai,
ChingHui Sia
Publication year - 2021
Publication title -
pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.51
H-Index - 59
eISSN - 1423-0313
pISSN - 0031-7012
DOI - 10.1159/000520903
Subject(s) - canagliflozin , meta analysis , medicine , amputation , randomized controlled trial , glycemic , dapagliflozin , hazard ratio , odds ratio , diabetes mellitus , surgery , confidence interval , type 2 diabetes , endocrinology , insulin
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly utilized in the treatment of diabetes mellitus as well as therapeutic extra-glycemic effects. However, there are still concerns over complications such as amputation events, given the results from the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial. Hence, we conducted a systematic review and meta-analysis of randomized-controlled trials to investigate the effect of SGLT2 inhibitors on amputation events. Methods: Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on November 21, 2020, for articles published from January 1, 2000, up to November 21, 2020, for studies that examined the effect of SGLT2 inhibitors on amputation events. Random-effect pair-wise meta-analysis for hazard ratios and fixed-effect Peto odds ratio meta-analysis were utilized to summarize the studies. Results: A total of 15 randomized-controlled trials were included with a combined cohort of 63,716 patients. We demonstrated that there was no significant difference in amputation events across different types of SGLT2 inhibitors, different baseline populations, and different duration of SGLT2 inhibitor use. Discussion/Conclusions: In this meta-analysis, SGLT2 inhibitors were not associated with a significant difference in amputation events.